Quarterly report pursuant to Section 13 or 15(d)

Document And Entity Information

Document And Entity Information - shares
6 Months Ended
Feb. 28, 2018
Apr. 12, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name ARTELO BIOSCIENCES, INC.  
Entity Central Index Key 0001621221  
Trading Symbol artl  
Current Fiscal Year End Date --08-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   12,781,195
Document Type 10-Q/A  
Document Period End Date Feb. 28, 2018  
Amendment Flag true  
Amendment Description


Artelo Biosciences, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the period ended February 28, 2018, which was originally filed on April 16, 2018 (the “Original Filing”). The purpose of this Amendment is to amend and restate Part I – Financial Information Item I – Financial Statements and Item II - Management's Discussion and Analysis of Financial Condition or Plan of Operation to record certain accrued research and development costs in the amount of $170,110 that was inadvertently omitted in the Original Filing.


Other than as set forth herein, this Amendment does not modify or update the Original Filing in any way, and the parts or exhibits of the Original Filing which have not been modified or updated are not included in this Amendment. This Amendment continues to speak as of the date of the Original Filing and the Company has not updated the disclosure contained herein to reflect events that have occurred since the filing of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Company’s other filings made with the Securities and Exchange Commission since the filing of the Original Filing, including amendments to those filings, if any.

Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2